A Case Series of Percutaneous Treatment of Non-Union Fractures with Autologous, Culture Expanded, Bone Marrow Derived, Mesenchymal Stem Cells and Platelet Lysate

Centeno, Christopher J.; Schultz, John R.; Cheever, Michelle

doi:10.4172/2155-9538.s2-007

Cited by 13 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Institutional Review Board oversight for the registry protocol was provided by a U.S. Office of Human Research Protections registered organization (#IRB00002637). Outcomes and efficacy of each procedure have been reported previously [2,8,13,16]. Prior to each procedure, physicians discussed risks, benefits, and alternatives to the procedure.…”

Section: Participants and Settingsmentioning

confidence: 99%

“…Because MSCs can differentiate into bone, cartilage, muscle, tendon, and ligament tissue and can use paracrine and other effects to elicit significant changes in injured tissues, their use for treating orthopaedic conditions holds significant promise [2][3][4][5]. In a clinical setting MSCs are typically harvested from bone marrow, then isolated and either re-injected or implanted in the same surgical procedure or culture expanded and then used clinically.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions

Centeno

Al‐Sayegh

Freeman

et al. 2016

International Orthopaedics (SICOT)

130

View full text Add to dashboard Cite

Introduction The purpose of the present investigation is to report on detailed complications among a much larger group of 2372 orthopaedic patients treated with stem cell injections who were followed in a treatment registry for up to nine years. Methods All patients underwent an MSC-based, percutaneous injection treatment of an orthopaedic condition between December 2005 and September 2014 at one of 18 clinical facilities. Treated areas of the body included the knee, hip, ankle/foot, hand/wrist, elbow, shoulder, and spine. The patients were followed prospectively via enrollment in a treatment registry. Patients were followed prospectively at one, three, six and 12 months, and annually thereafter, using an electronic system, ClinCapture software.Results A total of 3012 procedures were performed on 2372 patients with follow-up period of 2.2 years. A total of 325 adverse events were reported. The majority were pain postprocedure (n = 93, 3.9 % of the study population) and pain due to progressive degenerative joint disease (n = 90, 3.8 % of the study population). Seven cases reported neoplasms, a lower rate than in the general population. The lowest rate of adverse events was observed among patients injected with BMC alone. Conclusion Lowest rate of adverse events was among those patients receiving BMC injections alone, but the higher rate of AEs for BMC plus adipose and cultured cells was readily explained by the nature of the therapy or the longer followup. There was no clinical evidence to suggest that treatment Electronic supplementary material The online version of this article

show abstract

Section: Participants and Settingsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions

Centeno

Al‐Sayegh

Freeman

et al. 2016

International Orthopaedics (SICOT)

130

View full text Add to dashboard Cite

show abstract

“…This may well create enough traumas to make a whole marrow scaffold. Then, the fibrous tissue interposed between the bones ends can be ossified and stop the micro-motion at the delayed or nonunion site in order to allow union of the gap (Centeno C.J., 2011). All of 10 patients in our series healed their fracture.…”

Section: Discussionmentioning

confidence: 95%

“…Two cases with an intramedullary nail at the femoral and tibial fracture were dynamized by removal of the distal locking screw. In two cases of tibial fracture, external device was removed and the fracture was stabilized by plaster cast (Centeno C.J., 2011). …”

Section: Mscs Reimplantationmentioning

confidence: 99%

Mini-invasive treatment for delayed or nonunion: the use of percutaneous autologous bone marrow injection

Thua¹,

Pham²,

Le³

et al. 2015

Biomed Res Ther

View full text Add to dashboard Cite

Abstract-Delayed union or nonunion of bone fracture is becoming less frequent, but still remains a challenging clinical problem. Autologous cancellous bone grafting that is the gold standard method, often involves donor site morbidities and complications. Once these fractures have been mechanically stabilized, other local factors should be investigated to promote delayed healing. The purpose of this study was to evaluate the initial outcome of the percutaneous injection of autologous bone marrow after concentration for the treatment of delayed or nonunion. Our subjects included 10 patients (3 female, 7 male) with an average age of 28 years. All fractures were mechanically stabilized after accident.Delayed or nonunion affected the femur in 2 patients, the tibia in 5 patients, the humerus in 2 patients, and the ulna in 1 patient. Bone marrow aspirates were obtained from both the posterior superior iliac crest. Bone marrow aspiration concentrate was produced via density gradient centrifugation. Trocars were inserted in the delayed or nonunion gap under fluoroscopic guidance. The bone marrow aspiration concentrate was injected slowly. All of 10 delayed or nonunion healed after treatment with percutaneous injection of autologous bone marrow. The mean time for new bone formation was 3.3 months, for clinical union was 5.2 months, and for radiological union was 11.8 months. The result of current study is encouraging in the initial outcome and percutaneous bone marrow implantation could be an effective and safe treatment for delayed or nonunion.

show abstract

“…A follow up was done for 4.5 years and all patients reported a decline in the pain intensity and interference. Another very small pilot study by Centeno and group [38], where culture expanded mesenchymal stem cells were used to treat non-union in 6 patients (4 females, 2 males), and the treatment intervention was at an average of 8.75 months post-fracture, all but one patient showed improvement. The patient who lacked healing had a chronic fracture that lasted for more than 40 years.…”

Section: Discussionmentioning

confidence: 99%

Enhancement of Atrophic Non-Union Fracture Healing Using Autologous Progenitor Cell-Rich Bone Marrow

Venkatesh¹

2016

SRDT

View full text Add to dashboard Cite

There is growing interest in the use of bone marrow derived stem cells for bone repair. Increasing evidence now indicates that physiological bone remodelling occurs in close proximity to blood vessels and that these vessels carry perivascular stem cells that differentiate into osteoblasts. Non-union of bones are serious complication, incidences of which can be as high as 5% to 20%, varies by fracture site and is influenced by a number of fracture characteristics and host factors. The healing of fractures is a complex physiological process which could be interrupted by various factors. Thus, development of a novel therapeutic method to treat non-union fractures' becomes a clinical necessity. The purpose of this study was to assess the safety and efficacy of the autologous bone marrow concentrate preconditioned with synthetic graft in the treatment of non-union bone fractures. Autologous Bone Marrow Concentrate (aBMC) was prepared from bone marrow aspirate utilizing rapid, intraoperative point-of-care system via a density gradient centrifugation. A total of 17 patients were treated with aBMC at the fracture site and evaluated for the length of bone fracture healing time during the study follow-up period. The mean Total Nucleated Cell Count (TNCC) and Mononuclear Cell Count (MNCC) in all the patients were 5.54 x 10 8 ± 1.99 and 1.64 x 10 8 ± 0.86, respectively. 82% of the patients showed considerable bone healing of the non-union and the mean time for bone union/healing was 6 months. Overall the study concludes aBMC administration to be safe and effective in treating patients with atrophic non-unions and may contribute as an alternative to autologous cancellous bone graft.

show abstract

A Case Series of Percutaneous Treatment of Non-Union Fractures with Autologous, Culture Expanded, Bone Marrow Derived, Mesenchymal Stem Cells and Platelet Lysate

Cited by 13 publications

References 43 publications

A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions

A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions

Mini-invasive treatment for delayed or nonunion: the use of percutaneous autologous bone marrow injection

Enhancement of Atrophic Non-Union Fracture Healing Using Autologous Progenitor Cell-Rich Bone Marrow

Contact Info

Product

Resources

About